特一药业集团股份有限公司 2025年第三季度报告

Core Viewpoint - The company emphasizes the accuracy and completeness of its financial disclosures and reports, ensuring no misleading statements or significant omissions are present [1][2][9]. Financial Data - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. - As of September 30, 2025, the company repurchased 13,729,618 shares, representing 2.68% of its total share capital, with a total expenditure of approximately RMB 101.19 million [5]. Board Meeting - The sixth board meeting was held on October 23, 2025, with all six directors present, and the meeting complied with relevant legal and regulatory requirements [10]. - The board approved the third-quarter report for 2025, which had been reviewed and agreed upon by the audit committee [11][12].